Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration

PERSEUS - A Prospective Non-interventional Study to Assess the Effectiveness of Aflibercept (Eylea®) in Routine Clinical Practice in Patients With Wet Age-related Macular Degeneration

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01914380

Acronym

PERSEUS

Enrollment

988

Registered

2013-08-02

Start date

2013-07-29

Completion date

2017-03-31

Last updated

2018-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wet Age-related Macular Degeneration

Keywords

Wet age-related macular degeneration, Anti-VEGF-Therapy, Observational study

Brief summary

The study aims to investigate the effectiveness of Eylea in patients with wet age-related macular degeneration in routine clinical practice in Germany. The study is purely observational, only data from routine treatment are to be collected. The treatment and treatment conditions are solely at discretion of the treating physician.

Interventions

DRUGAflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Patients will be followed-up for 24 months

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with wet wAMD treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC). * Written informed consent.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Mean change of visual acuity for the total patient population	Baseline, 12 and 24 months
Mean change of visual acuity for the subgroup of pretreated patients	Baseline, 12 and 24 months
Mean change of visual acuity for the subgroup of non-pretreated patients	Baseline, 12 and 24 months

Secondary

Measure	Time frame	Description
Monitoring of disease activity	after 12 and 24 months	Monitoring of disease activity in routine clinical practice setting will be assessed e.g. by determining the o No. of clinical visits (visits for injections) o No. of monitoring visits (visits only for diagnostic purposes, but without injections) o No. of safety visits after the injection (visits only for safety checks after injection) o No. of visits outside the study center o No. of OCT (optical coherence tomography) assessments per patient after 12 and 24 months
Monitoring of treatment patterns	after 12 and 24 months	same assessment as indicated for Monitoring of disease activity
Mean time from indication of Eylea-treatment by the treating physician to start of treatment	after 12 and 24 months	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026